MTBVAC - one of the most promising new TB Vaccines with Dr Carlos Martín Montañés

Today we discuss the MTBVAC with Dr Montañés. MTBVAC is an attenuated vaccine from a human mycobacterial isolate which has just progressed to a phase 3 trial and shown very promising results in the phase 2 study. Dr Montañés has been involved in this project for over a decade and has an incredible insight into the development and promise of this vaccine for global TB epidemiology.ReferencesMartín, Carlos, et al. "MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG." Vaccine 39.50 (2021): 7277-7285.Achkar, Jacqueline M. "Prospects and challenges of a new live tuberculosis vaccine." The Lancet Respiratory Medicine 7.9 (2019): 723-725.Arbues, Ainhoa, et al. "Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials." Vaccine 31.42 (2013): 4867-4873.Tameris, Michele, et al. "Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial." The lancet Respiratory medicine 7.9 (2019): 757-770.Spertini, François, et al. "Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial." The lancet Respiratory medicine 3.12 (2015): 953-962.Gonzalo-Asensio, Jesus, et al. "MTBVAC: attenuating the human pathogen of tuberculosis (TB) toward a promising vaccine against the TB epidemic." Frontiers in immunology 8 (2017): 296893.